LONGEVERON INC-A(NASDAQ:LGVN) stock News

LGVN Latest News, Press Relases and Analysis

All

Press Releases

17 days ago - By: Chartmill - Mentions: SPNS TPIC RSLS ADD ...

These stocks have an unusual volume in today's session

18 days ago - By: Chartmill

Longeveron Inc. (NASDAQ:LGVN) Q2 2025 Earnings: Revenue Misses, EPS Narrower Than Expected

12 days ago - By: Longeveron

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

18 days ago - By: The Motley Fool

Longeveron Posts 32% Revenue Drop in Q2

18 days ago - By: Longeveron

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

19 days ago - By: Benzinga

Preview: Longeveron's Earnings

20 days ago - By: Longeveron

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

23 days ago - By: Longeveron

Longeveron Announces Up To $17.5 Million Public Offering

a month ago - By: Longeveron

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

a month ago - By: Longeveron

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

2 months ago - By: Longeveron

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

2 months ago - By: Longeveron

Longeveron® Appoints Than Powell as Chief Business Officer

2 months ago - By: Longeveron

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

3 months ago - By: Longeveron

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

3 months ago - By: Longeveron

Longeveron® to Attend BIO International Convention 2025

4 months ago - By: Longeveron

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

4 months ago - By: Longeveron

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

4 months ago - By: Longeveron

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Longeveron

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Benzinga - Mentions: MSC ELUT ACIW JYNT ...

Earnings Scheduled For May 8, 2025

4 months ago - By: Longeveron

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

4 months ago - By: Longeveron

Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

5 months ago - By: Longeveron

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease

6 months ago - By: Longeveron

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease

6 months ago - By: Longeveron

Longeveron® to Present at the 37th Annual Roth Conference

6 months ago - By: Longeveron

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

6 months ago - By: Longeveron

Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025

6 months ago - By: Longeveron

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

7 months ago - By: Longeveron

Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025

9 months ago - By: Longeveron

Longeveron to Present at Biotech Showcase 2025

9 months ago - By: Longeveron

LONGEVERON INC-A (LGVN) Stock News

LGVN Latest News, Press Relases and Analysis

These stocks have an unusual volume in today's session

Longeveron Inc. (NASDAQ:LGVN) Q2 2025 Earnings: Revenue Misses, EPS Narrower Than Expected

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Longeveron Posts 32% Revenue Drop in Q2

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Preview: Longeveron's Earnings

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Longeveron Announces Up To $17.5 Million Public Offering

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Longeveron® Appoints Than Powell as Chief Business Officer

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Longeveron® to Attend BIO International Convention 2025

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

Earnings Scheduled For May 8, 2025

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease

Longeveron® to Present at the 37th Annual Roth Conference

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025

Longeveron to Present at Biotech Showcase 2025

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024